stockrow
Monday 9 November 2026
Export ORMP’s income statement to Excel — free account
Oramed Pharmaceuticals Inc.
ORMPOramed Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 49.3% from fiscal 2023.
- Revenue
- +193.3%
- EPS
- +493.8%
- Free cash flow
- +94.3%
Quarter to June 2026, against a year earlier
3.86
0.03
−0.77%
Follow ORMP
Alert me
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Aug '22 | Dec '21 | Aug '21 | Aug '20 | Aug '19 | Aug '18 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
125.89 | 141.93 | 162.05 | 155.72 | 155.72 | 146.28 | 94.14 | 39.90 | 32.28 | 30.46 |
Total current assets |
133.27 | 143.22 | 162.58 | 157.11 | 157.11 | 147.94 | 95.34 | 40.51 | 33.32 | 31.04 |
Property, Plant, Equpment (Net) |
0.59 | 0.70 | 0.87 | 0.82 | 1.80 | 0.39 | 0.40 | 0.10 | 0.02 | 0.02 |
Long-Term Investments |
95.66 | 10.91 | 56.37 | 2.71 | 2.70 | 28.97 | 31.71 | 3.93 | 1.30 | 16.33 |
Long-term assets (Other) |
0.60 | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 |
Total non-current assets |
97.59 | 12.06 | 57.97 | 4.53 | — | 29.88 | 32.66 | 4.12 | 1.34 | 16.36 |
Total Assets |
230.86 | 155.28 | 220.55 | 161.64 | 161.64 | 177.82 | 128.00 | 44.63 | 34.66 | 47.40 |
Notes Payable |
— | — | 51.01 | — | — | — | — | — | — | — |
Accounts Payable |
6.85 | 5.47 | 1.93 | 4.16 | 2.18 | 4.54 | 3.85 | 1.79 | 2.61 | 2.10 |
Dividends Payable |
10.60 | — | — | — | — | — | — | — | — | — |
Current Revenue (Deferred) |
1.35 | — | — | 1.34 | — | 2.70 | 2.70 | 2.70 | 2.70 | 2.45 |
Total current liabilities |
19.09 | 5.69 | 53.21 | 5.75 | 5.75 | 7.37 | 6.68 | 4.54 | 5.31 | 4.55 |
Non-current Revenue (Deferred) |
3.27 | 4.00 | 4.00 | 4.00 | 4.00 | 3.34 | 4.24 | 6.95 | 9.66 | 11.39 |
Pension and Post-Retirement Liabilities |
0.04 | 0.03 | 0.03 | 0.02 | — | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Long Term Tax Liability (Deferred) |
7.91 | — | — | — | — | — | — | — | — | — |
Non-current Liabilities (Other) |
0.28 | 0.06 | 0.07 | 0.07 | 0.09 | 0.11 | 0.14 | 0.22 | 0.28 | 0.32 |
Total non-current liabilities |
12.03 | 4.25 | 4.44 | 4.74 | — | 3.84 | 4.80 | 7.22 | 9.96 | 11.73 |
Total liabilities |
31.12 | 9.93 | 57.66 | 10.49 | 10.49 | 11.21 | 11.48 | 11.75 | 15.27 | 16.29 |
Additional Paid In Capital |
322.71 | 322.40 | 320.89 | 314.42 | — | 292.51 | 230.20 | 125.21 | 100.29 | 99.43 |
Common Stock (Net) |
0.47 | 0.48 | 0.49 | 0.48 | 0.48 | 0.46 | 0.42 | 0.28 | 0.21 | 0.21 |
Retained Earnings |
(123.44) | (176.62) | (157.56) | (163.08) | (163.08) | (126.52) | (114.85) | (92.61) | (81.10) | (69.22) |
Common Equity (Total) |
199.74 | 145.35 | 162.89 | 151.16 | 151.81 | 166.61 | 116.52 | 32.88 | 19.39 | 31.11 |
Shareholders Equity (Total) |
199.74 | 145.35 | 162.89 | 151.16 | 151.81 | 166.61 | 116.52 | 32.88 | 19.39 | 31.11 |
Shareholders Equity and Liabilities (Total) |
230.86 | 155.28 | 220.55 | 161.64 | — | 177.82 | 128.00 | 44.63 | 34.66 | 47.40 |
Shares (Common) |
39.28 | 39.92 | 40.34 | 39.56 | — | 38.16 | 35.29 | 23.68 | 17.38 | 17.37 |
Shareholders Equity (Tangible) |
199.74 | 145.35 | 162.89 | 151.16 | — | 166.61 | 116.52 | 32.88 | 19.39 | 31.11 |
Net Debt |
(125.89) | (141.93) | (162.05) | (155.72) | (155.72) | (146.28) | (94.14) | (39.90) | (32.28) | (30.46) |
Total Debt |
— | — | — | — | 0.89 | — | 0.53 | 0.08 | — | — |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 2 Nov 2026